Author Archives: Magdalena Kegel

AgeneBio Obtains National Institute on Aging Grant for Phase 3 Trial of Its Alzheimer’s Therapy AGB101

AgeneBio has obtained a National Institute on Aging grant to conduct a Phase 3 clinical trial of AGB101 (levetiracetam), a compound intended to prevent people with mild memory impairment from developing Alzheimer’s disease. The agency, part of the National Institutes of Health (NIH), has been backing the potential therapy’s development for…